山东大学学报(医学版) ›› 2016, Vol. 54 ›› Issue (1): 52-57.doi: 10.6040/j.issn.1671-7554.0.2015.1042
张雪群1,高卫2,潘盼3,高骏逸4
ZHANG Xuequn1, GAO Wei2, PAN Pan3, GAO Junyi4
摘要: 目的 探讨PI3K/AKT信号通路中相关细胞因子PI3Kp110α、p-AKTser473、p-mTORser2448、CyclinD1在结肠癌组织中的表达及其与临床各病理参数之间的关系。 方法 采用免疫组织化学法检测65例结肠癌组织(结肠癌组)和15例结肠腺瘤组织(结肠腺瘤组)的PI3Kp110α、p-AKTser473、p-mTORser2448、CyclinD1的表达,分析各指标在结肠癌组的表达与临床各病理参数之间的关系。 结果 PI3Kp110α、p-AKTser473、p-mTORser2448、CyclinD1在结肠癌组中的阳性表达率均显著高于结肠腺瘤组,差异均有统计学意义(P<0.05)。PI3Kp110α、p-AKTser473、p-mTORser2448在结肠癌组的表达与性别、年龄、分化程度、是否淋巴结转移及TNM分期之间差异无统计学意义(P>0.05)。CyclinD1在不同分化程度及不同TNM分期的结肠癌组织中的表达有统计学差异(P<0.05),在不同性别、年龄及是否有淋巴结转移之间无明显差异(P>0.05)。PI3Kp110α、 p-AKTser473、p-mTORser2448、CyclinD1在结肠腺瘤组的阳性表达与性别、年龄、分化程度、是否淋巴结转移及TNM分期之间无统计学差异(P>0.05)。 结论 PI3Kp110α、 p-AKTser473、p-mTORser2448、CyclinD1的表达与结肠癌的发生发展密切相关,对结肠癌的预后评估及新靶点的研发具有重要意义。
中图分类号:
[1] Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012[J]. CA Cancer J Clin, 2012, 62(4):220-241. [2] Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2):69-90. [3] Ward E, Hao Y, Xu J. Cancer statistics[J]. CAJ Cancer Clin, 2009, 59(4):225-249. [4] Siegel R, Naishadham D, Jemal A. Cancer statistics[J]. CAJ Clin, 2013, 63(1):11-30. [5] Ward SG, Finan P. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents[J]. Curr Opin Pharmacol, 2003, 3(4):426-434. [6] Pene F, Claessens YE, Muller O, et a1. Role of the Dhosphatidylinositol 3-kinase/Akt and mT0R/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma[J]. Oncogene, 2002, 2l(43):6587-6597. [7] Rychahou PG, Murillo CA, Evers BM. Targeted RNA interference of PI3K pathway components sensitizes colon cancer cells to TNF-related apoptosis-inducing ligand(TRAIL)[J]. Surgery, 2005, 138(2):391-397. [8] Shao J, Washington MK, Saxena R, et al. Heterozygous disruption of the PTEN promotes intestinal neoplasia in APC min/+mouse roles of osteopontin[J]. Carcinogenesis, 2007, 28(12):2476-2483. [9] Ellis L, Ku SY, Ramakrishnan S, et al. Combinatorial antitumor effect of HDAC and the PI3K -Akt -mTOR pathway inhibition in a Pten deficient model of prostate cancer[J]. Oncotarget, 2013, 27(5):122-135. [10] Hales EC, Taub JW, Matherly LH, et al. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis:Targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia[J]. Cell Signal, 2014, 26(1):149-161. [11] Yentrapalli R, Azimzadeh O, Sriharshan A, et al. The PI3K/Akt/mTOR pathway is implicated in the premature senescence of primary human endothelial cells exposed to chronic radiation[J]. PLoS One, 2013, 11(1):181-226. [12] Slattery ML, Herrick JS, Lundgreen A, et al. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk:mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1[J]. Carcinogenesis, 2010, 31(9):1604-1611. [13] 彭秋平, 梁后杰, 边志衡, 等. mTOR信号通路调控HK-Ⅱ表达对结肠癌细胞增殖的影响[J]. 现代肿瘤医学, 2007, 15(6):760-762. [14] 李宝秀, 李春燕, 刘国龙, 等. 雷帕霉素靶蛋白在ⅢB期结肠癌中的异常表达及其意义[J]. 解放军医学杂志, 2010, 35(8):961-965. [15] Johnson SM, Gulhati P, Rampy BA, et al. Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer[J]. J Am Coll Surg, 2010, 210(5):767-776. [16] Cheung M, Testa JR. Diverse mechanisms of AKT pathway activation in human malignancy[J]. Curr Cancer Drug Targets, 2013, 13(3):234-244. [17] Viglietto G, Motti ML, Bruni P, et al. Cytoplasmic relocalization and inhibition of the cyclin- dependent kinase inhibitor p27(Kip1)by PKB/Akt-mediated phosphorylation in breast cancer[J]. Nat Med, 2002, 8(10):1136-1144. [18] Gao N, Zhang Z, Jiang BH, et al. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K /AKT /mTOR /p70S5K1 signaling in human ovarian cancer cells[J]. Am J Physiol Cell Physiol, 2004, 287(2):281-291. [19] Hua KQ, Feng WW, Cao Q, et al. Estrogen and progestin regulate metastasis through the PI3K /AKT pathway in human ovarian cancer[J]. Int J of Oncology, 2008, 33(5):959-967. [20] Morsaki T, Uchiyam A, Yuzuki D, et al. Interleukin 4 regulates G1 cell progression in colorectal carcinoma cell[J]. Cancer Res, 2004, 54(4):1113-1118. [21] 陈小贺, 孟文格, 孟繁杰, 等. CyclinD1、CDK4和Rb在大肠癌中的表达及意义[J]. 肿瘤防治研究, 2006, 33(6):428-430. |
[1] | 刘惠苓,王兴文,冯少滨,冯虹,韩俊庆. B类I型清道夫受体的高表达与结肠癌患者预后的相关性[J]. 山东大学学报(医学版), 2017, 55(10): 84-89. |
[2] | 王贲士, 单军奇,侯庆生,公为鹏,朱振宇,郭洪亮. CD11b+/CD66b-表型髓系细胞在结肠癌进展和肝转移中的作用[J]. 山东大学学报(医学版), 2017, 55(10): 41-45. |
[3] | 王尧, 陈艳红, 陈宏. 结肠癌患者外周血DPYD基因多态性与5-FU敏感性和毒副作用相关性分析[J]. 山东大学学报(医学版), 2014, 52(S1): 18-21. |
[4] | 仇会会1,叶丽平1,温有锋2,李丹1,宋佳1. IL-6对卵巢癌细胞bcl-2、cyclinD1和VEGF表达的影响[J]. 山东大学学报(医学版), 2014, 52(6): 17-21. |
[5] | 孟宪鹏1,刘杰2,苏娅3,邴雪4,高卫2. SU11274对人结肠癌LOVO细胞裸鼠移植瘤的抑制作用[J]. 山东大学学报(医学版), 2014, 52(2): 20-24. |
[6] | 李雪梅1, 颜世平1, 宿敬然2,程兆令1, 朱强1. TIPE2在结肠癌发展中的作用及分子机制[J]. 山东大学学报(医学版), 2014, 52(1): 20-22. |
[7] | 孙秀梅1,高峰2,刘子凤3. 盐霉素对结肠癌干细胞特性的抑制作用[J]. 山东大学学报(医学版), 2013, 51(9): 40-44. |
[8] | 任鹏1,郝青2,王杰书3,李洪林3,李波3,王峰3. 趋化因子受体3及血管生成拟态在结肠癌肝转移中的作用[J]. 山东大学学报(医学版), 2012, 50(8): 96-99. |
[9] | 李万全1,朱晓林2,于成功2. 丁酸钠对HT-29结肠癌细胞增殖及ICAM-1表达的影响[J]. 山东大学学报(医学版), 2010, 48(11): 70-. |
[10] | 马岚青1,郭永章2,张洪斌2,珠珠2,陈明清3,段丽平1. RNA干扰对小鼠结肠癌细胞VEGF表达及细胞增殖的影响[J]. 山东大学学报(医学版), 2010, 48(11): 63-69. |
|